tiprankstipranks
Trending News
More News >
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
Advertisement

TScan Therapeutics (TCRX) AI Stock Analysis

Compare
259 Followers

Top Page

TCRX

TScan Therapeutics

(NASDAQ:TCRX)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
$2.00
▲(8.11% Upside)
The overall stock score for TScan Therapeutics is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis provides some positive short-term signals, but the stock's valuation is concerning due to negative earnings and lack of dividends. The absence of earnings call data and corporate events means these factors do not impact the score.
Positive Factors
Revenue Growth
Strong revenue growth indicates expanding market presence and demand for TScan's innovative therapies, supporting long-term business viability.
High Gross Profit Margin
A high gross profit margin reflects effective cost control and pricing power, which can sustain profitability as revenue grows.
Moderate Leverage
Moderate leverage provides financial flexibility, allowing TScan to invest in growth opportunities without excessive debt burden.
Negative Factors
Negative Profitability
Ongoing negative profitability metrics highlight operational challenges, potentially limiting reinvestment and growth capabilities.
Negative Return on Equity
A negative return on equity indicates inefficiency in generating returns from shareholder investments, impacting investor confidence.
Cash Flow Challenges
Persistent cash flow difficulties can hinder TScan's ability to fund operations and strategic initiatives, affecting long-term sustainability.

TScan Therapeutics (TCRX) vs. SPDR S&P 500 ETF (SPY)

TScan Therapeutics Business Overview & Revenue Model

Company DescriptionTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
How the Company Makes MoneyTScan Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potentially through future sales of its therapeutic products once they receive regulatory approval. The company may enter into strategic partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the products developed from these collaborations. Additionally, TScan may receive funding through grants and other financial support aimed at advancing its research initiatives.

TScan Therapeutics Financial Statement Overview

Summary
TScan Therapeutics shows strong revenue growth but faces significant profitability challenges with negative margins. The balance sheet indicates moderate leverage and a solid equity base, yet the negative return on equity is concerning. Cash flow improvements are noted, but the company still faces cash flow difficulties.
Income Statement
45
Neutral
TScan Therapeutics shows a significant revenue growth rate of 57.45% in the TTM, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The high gross profit margin of 81.70% in the TTM suggests efficient cost management, but the overall negative margins highlight ongoing operational challenges.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio of 0.36 in the TTM indicates a moderate level of leverage, which is manageable. However, the negative return on equity of -63.84% suggests that the company is not generating sufficient returns for its shareholders. The equity ratio of 59.19% reflects a solid capital structure, but the overall financial health is weakened by the negative profitability metrics.
Cash Flow
40
Negative
TScan Therapeutics has a positive free cash flow growth rate of 6.03% in the TTM, showing some improvement in cash generation. However, the operating cash flow to net income ratio of -4.03 indicates significant cash flow challenges. The free cash flow to net income ratio of 1.04 suggests that the company is generating slightly more free cash flow than net income, but the overall cash flow situation remains strained.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.96M2.82M21.05M13.54M10.14M1.08M
Gross Profit6.25M2.82M-67.10M8.40M6.81M-19.49M
EBITDA-130.55M-119.74M-80.10M-59.91M-45.30M-25.00M
Net Income-136.78M-127.50M-89.22M-65.81M-48.63M-26.02M
Balance Sheet
Total Assets298.56M371.12M272.15M199.09M188.11M49.74M
Cash, Cash Equivalents and Short-Term Investments218.04M290.11M192.04M120.03M161.41M34.79M
Total Debt64.40M97.38M92.43M85.98M6.04M7.43M
Total Liabilities121.85M130.15M121.28M99.66M27.33M92.20M
Stockholders Equity176.71M240.97M150.87M99.43M160.78M-42.46M
Cash Flow
Free Cash Flow-131.25M-114.65M-64.50M-70.73M-58.62M-7.26M
Operating Cash Flow-126.18M-110.82M-61.36M-66.50M-48.68M-3.02M
Investing Cash Flow6.91M-52.61M-60.76M-4.22M-9.94M-4.24M
Financing Cash Flow46.51M208.76M135.44M29.36M189.67M288.00K

TScan Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.85
Price Trends
50DMA
1.79
Positive
100DMA
1.66
Positive
200DMA
1.89
Negative
Market Momentum
MACD
<0.01
Negative
RSI
54.67
Neutral
STOCH
82.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Positive. The current price of 1.85 is above the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.79, and below the 200-day MA of 1.89, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.67 is Neutral, neither overbought nor oversold. The STOCH value of 82.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRX.

TScan Therapeutics Risk Analysis

TScan Therapeutics disclosed 106 risk factors in its most recent earnings report. TScan Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TScan Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
94.64M-0.57-185.15%1.80%
48
Neutral
$104.98M-63.33%-42.94%
45
Neutral
92.38M-3.05-66.16%-87.65%11.76%
37
Underperform
81.63M-2.3062.83%
32
Underperform
34.50M-0.5322.94%
30
Underperform
179.72M-2.63-4.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TCRX
TScan Therapeutics
1.85
-3.13
-62.85%
ADVM
Adverum Biotechnologies
4.51
-2.51
-35.75%
ELTX
Elicio Therapeutics
11.00
5.97
118.69%
ADAG
Adagene
1.96
-0.26
-11.71%
CNTX
Context Therapeutics
0.91
-1.05
-53.57%
RANI
Rani Therapeutics Holdings
0.48
-1.68
-77.78%

TScan Therapeutics Corporate Events

Business Operations and Strategy
TScan Therapeutics Updates Corporate Milestones and Strategies
Neutral
Sep 9, 2025

On September 9, 2025, TScan Therapeutics released an updated corporate presentation outlining revised development and operational milestones, including adjusted timelines for its solid tumor program and updates on its pipeline for hematologic malignancies. The presentation, intended for investors and stakeholders, reflects the company’s ongoing efforts in target discovery initiatives in autoimmunity and highlights its strategic focus on advancing its TCR-T therapy candidates. This update is significant for stakeholders as it provides insights into TScan’s future growth strategies and its potential impact on the biotechnology industry.

The most recent analyst rating on (TCRX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 27, 2025